On September 6, 2021 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-and small molecule-based targeted therapeutics, reported that it will announce its Interim Results for the six month ended 30th June 2021 following a Board of Director’s meeting to be held on Tuesday 28th September 2021 (Press release, Philogen, SEP 6, 2021, View Source [SID1234587271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 12:00 ET / 17:00 BST / 18:00 CEST on September 29, 2021.

For more details or to attend the virtual briefing, please contact [email protected].